Innate Pharma (OTCMKTS:IPHYF) Trading 30.4% Higher - Still a Buy?

Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was up 30.4% during trading on Monday . The stock traded as high as $1.76 and last traded at $1.76. Approximately 150 shares were traded during trading, a decline of 90% from the average daily volume of 1,445 shares. The stock had previously closed at $1.35.

Innate Pharma Trading Down 17.6 %

The business has a 50-day moving average price of $2.73 and a two-hundred day moving average price of $2.44.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.